查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573003

芽生菌病市场：依治疗类型、给药途径、最终使用者、病患人口统计、疾病类型、诊断方法、产业 - 2025-2030 年全球预测

Blastomycosis Market by Treatment Type (Drug Treatment, Surgical Treatment), Route Of Administration (Inhalation, Intravenous, Oral), End User, Patient Demographics, Disease Type, Diagnostic Method, Industry - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年芽生菌市场价值为1.5634亿美元，预计到2024年将达到1.6194亿美元，复合年增长率为3.38%，到2030年将达到1.9731亿美元。

芽生菌病是一种由吸入芽生菌孢子引起的真菌感染疾病，通常会影响肺部，但也可能扩散到身体的其他部位。这种感染疾病的盛行率正在增加，特别是在有利于真菌生长的环境条件普遍存在的地区，增加了对增强诊断和治疗解决方案的需求。芽生菌病相关产品和服务市场包括诊断测试、抗真菌治疗以及医疗基础设施的改进，以有效检测和管理这种疾病。临床医生、医疗保健提供者和製药公司是这些产品的关键最终用户，用于早期检测和有效治疗、降低发病率并改善患者治疗结果。

主要市场统计
基准年[2023] 1.5634亿美元
预测年份 [2024] 16194万美元
预测年份 [2030] 1.9731 亿美元
复合年增长率（%） 3.38%

影响该市场的关键成长要素包括认识的提高和诊断率的提高，以及提高治疗效果的医疗技术的进步。特别是，芽生菌在北美地区是特有的，特别是在中西部以及密西西比河和俄亥俄河流域，这为市场扩张提供了巨大的机会。在开发具有更强功效和更少副作用的创新抗真菌药物以及部署人工智慧和机器学习以提高诊断准确性和流行病学追踪方面也存在潜在机会。

然而，抗真菌治疗的高昂费用、部分地区的诊断设施有限以及流行地区和非流行地区普遍缺乏认识导致诊断延迟，这已成为市场增长的一个问题。此外，目前治疗方法的副作用和抗药性模式可能会阻碍市场渗透和疗效。

为了促进创新，需要将研究重点放在开发具有成本效益的诊断测试和广谱抗真菌药物。此外，数位健康技术可用于创建教育计划，以提高医疗保健专业人员和公众的认识。旨在了解真菌发病机制的研究和合作将为标靶治疗的开发提供新的见解，相关人员将透过策略性投资研发来利用市场潜力。儘管芽生菌病解决方案的市场很小，但它透过技术主导和协作研究方法提供了重要的成长和创新机会。

市场动态：快速发展的芽生菌市场的关键市场洞察

供需的动态交互作用正在改变芽生菌市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 免疫力缺乏患者和社会弱势族群芽生菌病的发生率增加
    • 扩大医疗基础设施和诊断设施，促进芽生菌病的早期发现
    • 政府和非政府采取更多倡议来提高对真菌感染疾病的认识
    • 有效管理芽生菌病的联合治疗和创新治疗方法的出现
  • 市场限制因素
    • 研究经费不足和新治疗方法开发缓慢影响芽生菌病市场的成长
    • 地理和环境因素使芽生菌病患者分布不均和疾病控制工作变得更加复杂
  • 市场机会
    • 透过将芽生菌病诊断通讯协定纳入初级卫生保健来改善患者的治疗结果
    • 为医疗保健专业人员创建一个教育计划，重点是识别和管理芽生菌病病例
    • 研发新检测技术，更快更精确鑑定芽生菌属
  • 市场挑战
    • 芽生菌病市场的新药和治疗方法存在监管障碍和漫长的核准流程
    • 芽生菌病研究和开发倡议的资金和投资不足

波特的五力：驾驭芽孢菌市场的策略工具

波特的五力架构是了解芽生菌病市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解芽生菌市场的外部影响

外部宏观环境因素在塑造芽生菌市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解芽生菌市场的竞争状况

对芽生菌市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵芽生菌病市场供应商的绩效评估

FPNV 定位矩阵是评估芽生菌市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了芽生菌市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对芽生菌市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 免疫力缺乏和脆弱族群中芽生菌病的发生率增加
      • 扩大医疗基础设施和诊断设施，以加速芽生菌病的早期发现
      • 加强政府和非政府努力，提高对真菌感染疾病的认识
      • 有效治疗芽生菌病的联合治疗和创新治疗方法的出现
    • 抑制因素
      • 研究经费不足和新治疗方法开发缓慢正在影响芽生菌病市场的成长
      • 地理和环境因素导致芽生菌病病例分布不均，使疾病管制工作复杂化
    • 机会
      • 将芽生菌病诊断通讯协定纳入初级卫生保健机构，以改善患者的治疗结果
      • 为医疗保健专业人员创建一个教育计划，重点是识别和管理芽生菌病病例
      • 研究和开发新的实验技术，以更快、更准确地鑑定芽生菌属。
    • 任务
      • 新药和治疗方法芽生菌病市场的监管障碍和核准流程的长度
      • 芽生菌病研究和开发倡议的资金和投资不足
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章芽生菌病市场：依治疗类型

  • 药物治疗
    • 抗真菌药物
    • 类固醇
  • 手术治疗
    • 排水程序
    • 切除术

第七章芽生菌市场：依给药途径

  • 吸入
  • 静脉
  • 口服

第 8 章芽生菌市场：依最终用户分类

  • 家庭护理设置
  • 医院
  • 专科诊所

第 9 章芽生菌病市场：依病患属性

  • 成人用
  • 老年病
  • 小儿科

第 10 章芽生菌市场：依疾病类型

  • 急性芽生菌病
  • 慢性芽生菌病
  • 分布式芽生菌病

第十一章芽生菌市场：依诊断方法

  • 临床检查
  • 影像检查
  • 临床检查

第十二章芽生菌市场：依行业分类

  • 生技公司
  • 製药公司
  • 研究所

第十三章美洲芽生菌市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十四章亚太芽生菌市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章欧洲、中东和非洲的芽生菌市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0289

The Blastomycosis Market was valued at USD 156.34 million in 2023, expected to reach USD 161.94 million in 2024, and is projected to grow at a CAGR of 3.38%, to USD 197.31 million by 2030.

Blastomycosis is a fungal infection caused by inhaling spores of the Blastomyces species, typically affecting the lungs but potentially spreading to other body parts. The rising incidence of this infection, particularly in regions with prevalent environmental conditions conducive to fungal growth, is driving the necessity for enhanced diagnostic and treatment solutions. The market for blastomycosis-related products and services includes diagnostic tests, antifungal therapies, and healthcare infrastructure improvements to detect and manage the disease effectively. Clinicians, healthcare providers, and pharmaceutical companies represent primary end-users, who utilize these offerings to ensure early detection and effective treatment, thereby reducing morbidity and improving patient outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 156.34 million
Estimated Year [2024] USD 161.94 million
Forecast Year [2030] USD 197.31 million
CAGR (%) 3.38%

Key growth factors impacting this market include increased awareness and improved diagnosis rates, alongside advancements in medical technology that enhance treatment efficacy. Notably, the geographic prevalence of Blastomyces species in North America, particularly the Midwest and regions along the Mississippi and Ohio River valleys, presents significant opportunities for market expansion. Potential opportunities also lie in developing innovative antifungal drugs with better efficacy and reduced side effects, as well as incorporating AI and machine learning to improve diagnostic accuracy and epidemiological tracking.

However, market growth is challenged by factors such as the high cost of antifungal treatments, limited availability of diagnostic facilities in some regions, and a general lack of awareness in endemic and non-endemic areas leading to delayed diagnosis. Moreover, side effects of current treatment modalities and resistance patterns could hinder market penetration and effectiveness.

To foster innovation, there is a need for research focused on developing cost-effective diagnostic tests and broad-spectrum antifungal agents. Additionally, leveraging digital health technologies to create educational programs could enhance awareness among health professionals and the general public. Research and collaboration aimed at understanding fungal pathogenesis will offer new insights for targeted treatment development, providing ample opportunities for stakeholders to capitalize on market potential with a strategic approach towards investment in R&D. The market for blastomycosis solutions, while niche, offers substantial opportunities for growth and innovation through technology-driven and collaborative approaches.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blastomycosis Market

The Blastomycosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidence of blastomycosis in immunocompromised individuals and vulnerable populations
    • Expansion of healthcare infrastructure and diagnostic facilities accelerating early detection of blastomycosis
    • Increasing government and non-government initiatives for raising awareness about fungal infections
    • Emergence of combination therapies and innovative treatment modalities for effective management of blastomycosis
  • Market Restraints
    • Inadequate research funding and slow development of new treatments affecting blastomycosis market growth
    • Geographic and environmental factors contributing to uneven distribution of blastomycosis cases and complicating disease control efforts
  • Market Opportunities
    • Integration of blastomycosis diagnostic protocols in primary healthcare settings to improve patient outcomes
    • Creation of educational programs for healthcare professionals focusing on the identification and management of blastomycosis cases
    • Research and development of new laboratory techniques for faster and more accurate identification of blastomyces species
  • Market Challenges
    • Regulatory hurdles and lengthy approval process for new drugs and treatments in the blastomycosis market
    • Insufficient funding and investment in blastomycosis research and development initiatives

Porter's Five Forces: A Strategic Tool for Navigating the Blastomycosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blastomycosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blastomycosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blastomycosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blastomycosis Market

A detailed market share analysis in the Blastomycosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blastomycosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blastomycosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blastomycosis Market

A strategic analysis of the Blastomycosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blastomycosis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., Astellas Pharma Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Vertex Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Blastomycosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Drug Treatment and Surgical Treatment. The Drug Treatment is further studied across Antifungals and Steroids. The Surgical Treatment is further studied across Drainage Procedures and Lung Lobectomy.
  • Based on Route Of Administration, market is studied across Inhalation, Intravenous, and Oral.
  • Based on End User, market is studied across Homecare Settings, Hospitals, and Specialty Clinics.
  • Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Disease Type, market is studied across Acute Blastomycosis, Chronic Blastomycosis, and Disseminated Blastomycosis.
  • Based on Diagnostic Method, market is studied across Clinical Examination, Imaging Tests, and Laboratory Tests.
  • Based on Industry, market is studied across Biotechnology Firms, Pharmaceutical Companies, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of blastomycosis in immunocompromised individuals and vulnerable populations
      • 5.1.1.2. Expansion of healthcare infrastructure and diagnostic facilities accelerating early detection of blastomycosis
      • 5.1.1.3. Increasing government and non-government initiatives for raising awareness about fungal infections
      • 5.1.1.4. Emergence of combination therapies and innovative treatment modalities for effective management of blastomycosis
    • 5.1.2. Restraints
      • 5.1.2.1. Inadequate research funding and slow development of new treatments affecting blastomycosis market growth
      • 5.1.2.2. Geographic and environmental factors contributing to uneven distribution of blastomycosis cases and complicating disease control efforts
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of blastomycosis diagnostic protocols in primary healthcare settings to improve patient outcomes
      • 5.1.3.2. Creation of educational programs for healthcare professionals focusing on the identification and management of blastomycosis cases
      • 5.1.3.3. Research and development of new laboratory techniques for faster and more accurate identification of blastomyces species
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles and lengthy approval process for new drugs and treatments in the blastomycosis market
      • 5.1.4.2. Insufficient funding and investment in blastomycosis research and development initiatives
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Blastomycosis Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Drug Treatment
    • 6.2.1. Antifungals
    • 6.2.2. Steroids
  • 6.3. Surgical Treatment
    • 6.3.1. Drainage Procedures
    • 6.3.2. Lung Lobectomy

7. Blastomycosis Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Intravenous
  • 7.4. Oral

8. Blastomycosis Market, by End User

  • 8.1. Introduction
  • 8.2. Homecare Settings
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Blastomycosis Market, by Patient Demographics

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Blastomycosis Market, by Disease Type

  • 10.1. Introduction
  • 10.2. Acute Blastomycosis
  • 10.3. Chronic Blastomycosis
  • 10.4. Disseminated Blastomycosis

11. Blastomycosis Market, by Diagnostic Method

  • 11.1. Introduction
  • 11.2. Clinical Examination
  • 11.3. Imaging Tests
  • 11.4. Laboratory Tests

12. Blastomycosis Market, by Industry

  • 12.1. Introduction
  • 12.2. Biotechnology Firms
  • 12.3. Pharmaceutical Companies
  • 12.4. Research Institutes

13. Americas Blastomycosis Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Blastomycosis Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Blastomycosis Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. Bayer AG
  • 6. Biogen Inc.
  • 7. Boehringer Ingelheim GmbH
  • 8. Bristol-Myers Squibb Company
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Roche Holding AG
  • 17. Sanofi S.A.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Vertex Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. BLASTOMYCOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. BLASTOMYCOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLASTOMYCOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. BLASTOMYCOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. BLASTOMYCOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLASTOMYCOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLASTOMYCOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLASTOMYCOSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DRAINAGE PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY LUNG LOBECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY ACUTE BLASTOMYCOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CHRONIC BLASTOMYCOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DISSEMINATED BLASTOMYCOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY CLINICAL EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BLASTOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES BLASTOMYCOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BLASTOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 314. POLAND BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 323. QATAR BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 332. RUSSIA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. RUSSIA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 334. RUSSIA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 340. RUSSIA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 341. SAUDI ARABIA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 342. SAUDI ARABIA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 343. SAUDI ARABIA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 344. SAUDI ARABIA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 345. SAUDI ARABIA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 346. SAUDI ARABIA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 347. SAUDI ARABIA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 348. SAUDI ARABIA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 349. SAUDI ARABIA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 350. SOUTH AFRICA BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 351. SOUTH AFRICA BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 352. SOUTH AFRICA BLASTOMYCOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 353. SOUTH AFRICA BLASTOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 354. SOUTH AFRICA BLASTOMYCOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 355. SOUTH AFRICA BLASTOMYCOSIS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 356. SOUTH AFRICA BLASTOMYCOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. SOUTH AFRICA BLASTOMYCOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 358. SOUTH AFRICA BLASTOMYCOSIS MARKET SIZE, BY INDUSTRY, 2018-2030 (USD MILLION)
  • TABLE 359. SPAIN BLASTOMYCOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 360. SPAIN BLASTOMYCOSIS MARKET SIZE, BY DRUG TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 361. SPAIN BLASTOMYCOSIS MARKET SIZE, BY SURGIC